![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessCore-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”
-
Article
Open AccessClinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set
-
Article
Open AccessFlow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
-
Article
Open AccessPrognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients
Current prognostic models for myelodysplastic syndromes (MDS), including the Revised International Prognostic Scoring System (IPSS-R), do not account for host immunity. We retrospectively examined the prognost...
-
Article
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis
-
Article
Open AccessNumber and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
-
Article
Open AccessSurvival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment
-
Article
Open AccessImetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
-
Article
Open AccessCytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
Chronic myelomonocytic leukemia (CMML) is a clonal stem cell disorder associated with peripheral blood monocytosis and an inherent tendency to transform to acute myeloid leukemia. CMML has overlap** features...
-
Article
Open AccessPrognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
Mutations involving epigenetic regulators (TET2~60% and ASXL1~40%) and splicing components (SRSF2~50%) are frequent in chronic myelomonocytic leukemia (CMML). On a 27-gene targeted capture panel performed on 175 ...
-
Article
Open AccessAn international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
Since its reclassification as a distinct disease entity, clinical research efforts have attempted to establish baseline characteristics and prognostic scoring systems for chronic myelomonocytic leukemia (CMML)...
-
Article
Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells
-
Article
Open AccessASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
-
Article
Erratum: Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
Correction to: Blood Cancer Journal (2015) 4, e270; doi:10.1038/bcj.2014.90; published online 2 January 2015 Since publication, the publishers have identified that this article was incorrectly placed in volume...
-
Article
Open AccessChronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
In patients with chronic myelomonocytic leukemia (CMML), age>65 years is an adverse prognostic factor. Our objective in the current study was to examine risk factors for survival and treatment outcome in 261 ‘...
-
Article
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
In a cohort of 466 patients, we sought to clarify the prognostic relevance of ASXL1 and SETBP1 mutations, among others, in World Health Organization-defined chronic myelomonocytic leukemia (CMML) and its added va...
-
Article
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts
-
Article
Erratum: Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
Correction to: Leukemia (2013) 27, 1504–1510; doi:10.1038/leu.2013.88 Since the publication of this article, the authors have identified an error concerning to one of the author names. RS Komroji should have b...
-
Article
Open AccessSETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
-
Article
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of ‘tumor burden’ but also in terms of their underlying biology. High-dos...